Senzar Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Senzar Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-135,535	Closed	-$5.62M	–	45
2015 Q4	$5.62M	Buy	+135,535	New	+$4.54M	0.63%	29
2015 Q1	–	Sell	-332,474	Closed	-$8.98M	–	43
2014 Q4	$8.98M	Buy	332,474 +34,174	+11%	+$588K	2.63%	18
2014 Q3	$3.5M	Buy	298,300 +36,300	+14%	+$458K	1.03%	23
2014 Q2	$4.07M	Buy	262,000 +213,300	+438%	+$3.06M	1.56%	22
2014 Q1	$958K	Buy	+48,700	New	+$827K	0.51%	18

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Senzar Asset Management's FPRX Position: Q1 2016 in Review

Senzar Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2016, closing a stake of 135,535 shares — an estimated $5.62M sold.

Senzar Asset Management first reported a position in FPRX in Q1 2014 and held it in 5 quarters. The position peaked at $8.98M in Q4 2014. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

Senzar Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Senzar Asset Management sold 135,535 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $5.62M.
Senzar Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 5 quarters.
Senzar Asset Management's Five Prime Therapeutics, Inc. position peaked at $8.98M in Q4 2014.
140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Senzar Asset Management's 13F filing for Q1 2016, filed 13 May 2016.